HB 131 creates a new section of Florida Statutes governing dense breast tissue screenings. It provides that a patient who has previously been identified as having dense breast tissue in a mammography report may receive an ultrasound or other additional screening tests without first undergoing a conventional mammogram. The bill defines “mammography report” by reference to federal regulation and sets the act to take effect on July 1, 2025.
In practical terms, the bill removes a procedural barrier for patients with dense breast tissue who may need supplemental imaging. It does not mandate that additional screening be performed, but it authorizes access to ultrasound or other follow-up tests based on a prior dense-breast finding, which may affect screening practices, ordering protocols, and insurance or provider workflows in Florida.
Impact
The bill would add s. 381.94, Florida Statutes, creating a specific state-law authorization for supplemental breast screening after a dense-breast finding. It affects patients, radiology providers, and potentially insurers and health systems by allowing additional imaging without requiring a repeat conventional mammogram first. The bill also incorporates a federal definition of mammography report, tying the new state provision to existing federal regulatory language.
Sentiment
No committee transcripts or recorded votes were provided, so there is no direct evidence of debate or opposition in the available materials. Based on the bill text and caption, the measure appears narrowly targeted and medically focused, suggesting a generally practical or supportive policy approach rather than a controversial one. The absence of recorded legislative discussion makes the overall sentiment difficult to gauge beyond the bill’s straightforward, patient-access framing.
Contention
The main potential point of contention is whether allowing ultrasound or other additional screening tests without first requiring a conventional mammogram could alter standard screening pathways, increase utilization, or affect costs and coverage decisions. Any disagreement would likely center on medical necessity, insurance reimbursement, and whether the bill changes clinical practice for patients with dense breast tissue. However, no specific objections or supporters are identified in the provided record.